Cargando…

Virtual screening and experimental validation of novel histone deacetylase inhibitors

BACKGROUND: Histone deacetylases (HDACs) are promising therapeutic targets for the treatment of cancer, diabetes and other human diseases. HDAC inhibitors, as a new class of potential therapeutic agents, have attracted a great deal of interest for both research and clinical applications. Increasing...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yan-xin, Zhao, Jian, Song, Qiu-hang, Zheng, Li-hua, Fan, Cong, Liu, Ting-ting, Bao, Yong-li, Sun, Lu-guo, Zhang, Li-biao, Li, Yu-xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955146/
https://www.ncbi.nlm.nih.gov/pubmed/27443303
http://dx.doi.org/10.1186/s40360-016-0075-8
_version_ 1782443895037100032
author Huang, Yan-xin
Zhao, Jian
Song, Qiu-hang
Zheng, Li-hua
Fan, Cong
Liu, Ting-ting
Bao, Yong-li
Sun, Lu-guo
Zhang, Li-biao
Li, Yu-xin
author_facet Huang, Yan-xin
Zhao, Jian
Song, Qiu-hang
Zheng, Li-hua
Fan, Cong
Liu, Ting-ting
Bao, Yong-li
Sun, Lu-guo
Zhang, Li-biao
Li, Yu-xin
author_sort Huang, Yan-xin
collection PubMed
description BACKGROUND: Histone deacetylases (HDACs) are promising therapeutic targets for the treatment of cancer, diabetes and other human diseases. HDAC inhibitors, as a new class of potential therapeutic agents, have attracted a great deal of interest for both research and clinical applications. Increasing efforts have been focused on the discovery of HDAC inhibitors and some HDAC inhibitors have been approved for use in cancer therapy. However, most HDAC inhibitors, including the clinically approved agents, do not selectively inhibit the deacetylase activity of class I and II HDAC isforms, and many suffer from metabolic instability. This study aims to identify new HDAC inhibitors by using a high-throughput virtual screening approach. METHODS: An integration of in silico virtual screening and in vitro experimental validation was used to identify novel HDAC inhibitors from a chemical database. RESULTS: A virtual screening workflow for HDAC inhibitors were created by integrating ligand- and receptor- based virtual screening methods. Using the virtual screening workflow, 22 hit compounds were selected and further tested via in vitro assays. Enzyme inhibition assays showed that three of the 22 compounds had HDAC inhibitory properties. Among these three compounds, ZINC12555961 significantly inhibited HDAC activity. Further in vitro experiments indicated that ZINC12555961 can selectively inhibit proliferation and promote apoptosis of cancer cells. CONCLUSIONS: In summary, our study presents three new and potent HDAC inhibitors and one of these HDAC inhibitors shows anti-proliferative and apoptosis-inducing activity against various cancer cell lines. These results suggest that the developed virtual screening workflow can provide a useful source of information for the screening and validation of new HDAC inhibitors. The new-found HDAC inhibitors are worthy to further and more comprehensive investigations. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40360-016-0075-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4955146
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49551462016-07-22 Virtual screening and experimental validation of novel histone deacetylase inhibitors Huang, Yan-xin Zhao, Jian Song, Qiu-hang Zheng, Li-hua Fan, Cong Liu, Ting-ting Bao, Yong-li Sun, Lu-guo Zhang, Li-biao Li, Yu-xin BMC Pharmacol Toxicol Research Article BACKGROUND: Histone deacetylases (HDACs) are promising therapeutic targets for the treatment of cancer, diabetes and other human diseases. HDAC inhibitors, as a new class of potential therapeutic agents, have attracted a great deal of interest for both research and clinical applications. Increasing efforts have been focused on the discovery of HDAC inhibitors and some HDAC inhibitors have been approved for use in cancer therapy. However, most HDAC inhibitors, including the clinically approved agents, do not selectively inhibit the deacetylase activity of class I and II HDAC isforms, and many suffer from metabolic instability. This study aims to identify new HDAC inhibitors by using a high-throughput virtual screening approach. METHODS: An integration of in silico virtual screening and in vitro experimental validation was used to identify novel HDAC inhibitors from a chemical database. RESULTS: A virtual screening workflow for HDAC inhibitors were created by integrating ligand- and receptor- based virtual screening methods. Using the virtual screening workflow, 22 hit compounds were selected and further tested via in vitro assays. Enzyme inhibition assays showed that three of the 22 compounds had HDAC inhibitory properties. Among these three compounds, ZINC12555961 significantly inhibited HDAC activity. Further in vitro experiments indicated that ZINC12555961 can selectively inhibit proliferation and promote apoptosis of cancer cells. CONCLUSIONS: In summary, our study presents three new and potent HDAC inhibitors and one of these HDAC inhibitors shows anti-proliferative and apoptosis-inducing activity against various cancer cell lines. These results suggest that the developed virtual screening workflow can provide a useful source of information for the screening and validation of new HDAC inhibitors. The new-found HDAC inhibitors are worthy to further and more comprehensive investigations. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40360-016-0075-8) contains supplementary material, which is available to authorized users. BioMed Central 2016-07-21 /pmc/articles/PMC4955146/ /pubmed/27443303 http://dx.doi.org/10.1186/s40360-016-0075-8 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Huang, Yan-xin
Zhao, Jian
Song, Qiu-hang
Zheng, Li-hua
Fan, Cong
Liu, Ting-ting
Bao, Yong-li
Sun, Lu-guo
Zhang, Li-biao
Li, Yu-xin
Virtual screening and experimental validation of novel histone deacetylase inhibitors
title Virtual screening and experimental validation of novel histone deacetylase inhibitors
title_full Virtual screening and experimental validation of novel histone deacetylase inhibitors
title_fullStr Virtual screening and experimental validation of novel histone deacetylase inhibitors
title_full_unstemmed Virtual screening and experimental validation of novel histone deacetylase inhibitors
title_short Virtual screening and experimental validation of novel histone deacetylase inhibitors
title_sort virtual screening and experimental validation of novel histone deacetylase inhibitors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955146/
https://www.ncbi.nlm.nih.gov/pubmed/27443303
http://dx.doi.org/10.1186/s40360-016-0075-8
work_keys_str_mv AT huangyanxin virtualscreeningandexperimentalvalidationofnovelhistonedeacetylaseinhibitors
AT zhaojian virtualscreeningandexperimentalvalidationofnovelhistonedeacetylaseinhibitors
AT songqiuhang virtualscreeningandexperimentalvalidationofnovelhistonedeacetylaseinhibitors
AT zhenglihua virtualscreeningandexperimentalvalidationofnovelhistonedeacetylaseinhibitors
AT fancong virtualscreeningandexperimentalvalidationofnovelhistonedeacetylaseinhibitors
AT liutingting virtualscreeningandexperimentalvalidationofnovelhistonedeacetylaseinhibitors
AT baoyongli virtualscreeningandexperimentalvalidationofnovelhistonedeacetylaseinhibitors
AT sunluguo virtualscreeningandexperimentalvalidationofnovelhistonedeacetylaseinhibitors
AT zhanglibiao virtualscreeningandexperimentalvalidationofnovelhistonedeacetylaseinhibitors
AT liyuxin virtualscreeningandexperimentalvalidationofnovelhistonedeacetylaseinhibitors